PhI/II AZA/VEN/MAG - Slideset Download - | CCO
Magrolimab plus azacitidine results in promising activity in higher-risk MDS patients
Forty Seven: Buy The Dip In This CD47 Pioneer Ahead Of ASCO GI (NASDAQ:FTSV) | Seeking Alpha
Forty Seven, Inc. Announces Updated Data from Ongoing Clinical Trial of Magrolimab Showing Robust, Durable Activity in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia-CliniExpert
Efficacy of magrolimab + azacitidine in untreated AML and MDS patients. | Download Scientific Diagram
JCM | Free Full-Text | Current Therapy of the Patients with MDS: Walking towards Personalized Therapy
Guidance for transfusion management in patients receiving magrolimab therapy (anti‐CD47 monoclonal antibody) - Tan - 2022 - Internal Medicine Journal - Wiley Online Library
New directions for emerging therapies in acute myeloid leukemia: the next chapter | Blood Cancer Journal
Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy | Signal Transduction and Targeted Therapy
ENHANCE-3 Trial of Magrolimab in Combination with Venetoclax and Azacitidine in AML
EHA Library - The official digital education library of European Hematology Association (EHA)
Magrolimab + Aza for AML - Slideset Download - Clinical Oncology 2022 | CCO
Forty Seven: Buy The Dip In This CD47 Pioneer Ahead Of ASCO GI (NASDAQ:FTSV) | Seeking Alpha
Magrolimab - Multiple Myeloma Clinical Trials
Magrolimab for Solid Tumors Clinical Trial 2023 | Power
Magrolimab Demonstrates Clinical Responses in Ongoing Phase 1b Trial of Previously Untreated Acute Myeloid Leukemia Patients | Leukemia and Lymphoma Society
ASCO News - Magrolimab in Combination with Azacitidine Demonstrates Durable Activity in Untreated MDS & AML | Leukemia and Lymphoma Society
Magrolimab combination with azacitidine enhances therapeutic... | Download Scientific Diagram
A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma - ScienceDirect
Effect of CD47 Blockade on Vascular Inflammation | NEJM
Brian Skorney on Twitter: "Magrolimab + aza data out. CR rate in 2019 was 50% in high risk MDS. Down to 42% in 2020. Now 33% today. Contrast with 32% CR with
Magrolimab + Azacitidine vs Venetoclax Acute Myeloid Leukemia
New Research on Magrolimab Provides Key Insights as Gilead Rapidly Expands Research in AML | Leukemia and Lymphoma Society
Forty Seven (FTSV) On A Roll, Up Over 300% In 2 Months
FDA Lifts Partial Clinical Hold on MDS and AML Magrolimab Studies | Business Wire
Corporate Overview
